Skip to main content
. 2019 May 17;70(7):1267–1274. doi: 10.1093/cid/ciz407

Figure 3.

Figure 3.

Changes in weight within 18 months of treatment initiation among persons living with human immunodeficiency virus starting dolutegravir and nonnucleoside reverse transcriptase inhibitors (A) or dolutegravir and protease inhibitors (B). Abbreviations: ART, antiretroviral therapy; DTG, dolutegravir; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.